Provisions for Drug Advertisement Examination

作者:法律资料网 时间:2024-07-23 16:33:25   浏览:8086   来源:法律资料网
下载地址: 点击此处下载

Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


下载地址: 点击此处下载
我国的政府采购模式尚存缺陷
文章来源:中国经济时报
发表时间:2005年5月27日
作者: ■谷辽海

选择什么样的采购模式更有利于控制和规范公共消费行为,管理好公共资金,提高采购效率,实现公共政策目标,在各个国家和地区都不尽相同。

美国政府采购模式分集中采购和分散采购两种。采购金额在2500美元以内的实行分散采购,采购金额在2500美元以上的实行集中采购。韩国在中央政府设立采购供应厅,是世界上实行集中采购模式的典型代表。我国香港地区政府采购也实行集中采购制度,只有小额物品由各部门分散采购。

对于分散采购模式,我们都不陌生。过去,我国长期实行各部门、各单位自行采购的模式。而集中采购模式,是指本级政府各部门所需要的货物、工程和服务由本级政府所设的集中采购机构统一实施。相对于分散采购来说,集中采购有自己的明显优势:一是有利于充分形成公平的竞争环境,实现物有所值的目标。二是增大采购规模和效率,降低成本,形成买方市场。三是有利于政府采购活动的监督和管理,防止暗箱操作。四是有利于国家对经济宏观调控,实现公共政策目标。五是有利于提高政府采购技术水平,向专业化发展,减少重复采购和浪费。但是,集中采购也有其局限性,缺乏灵活快捷,不能很好地满足使用部门的需求。

政府采购模式的选择,实质上是对政府采购效益和效率的选择问题。根据政府采购两种模式的各自特点,结合中国实际情况,我国《政府采购法》第七条规定,政府采购实行集中采购和分散采购相结合。按照现行法律,凡是未被纳入集中采购目录以内、达到限额标准以上的采购对象,仍由各部门、各单位实行分散采购。据笔者理解,实际上,我国分散采购的还有许多尚未达到限额标准的采购项目。例如:《中央预算单位2005年政府集中采购目录及标准》规定,除政府集中采购目录和部门集中采购项目外,各部门自行采购达到50万元以上的货物和服务的项目、60万元以上的工程项目。显然,在限额标准以下的采购对象,如果未被纳入政府采购目录,一方面是属于部门有权力自行采购;另一方面也是属于法律的真空地带,效力范围之外。可见,政府采购法还是存在着很大的缺陷。

实践中比较突出的问题是,也是灰色交易频繁曝光的重大建设项目,往往都发生在分散采购领域。由于没有法定义务将采购项目交给集中采购机构,采购人也就有机会与以营利为目的社会中介机构招标公司进行“合作”,提高采购预算和中标价格,从中赚取巨额的回扣和酬金(一般为20-40%)回报。

可见,法律的缺位为公共权力设租人和寻租人提供了“合法”的交易场所。根据政府采购法第十八条规定,采购人采购纳入集中采购目录的政府采购项目,必须委托集中采购机构代理采购。财政部出台的行政规章,将集中采购又分为政府集中采购和部门集中采购,规定后者可以委托社会中介招标采购机构进行代理,所出台的《政府集中采购目录及标准》中,特别列出了部门集中采购的范围,其实质就是分散采购。

笔者认为,这种划分,严重违反了法律强制性规定。部门集中采购也是属于政府集中采购,为维护法制统一,必须委托集中采购机构代理。由于行政规章严重违反了上位法的规定,2003年我国集中采购规模为1025亿元,占采购总量的61%,然而自去年开始,我国的集中采购规模明显出现被逐渐压缩而分散采购规模不断扩大的趋势,而且愈演愈烈。这一现象的出现,除了行政规章突破法律框架之外,还有行政自由裁量权不受任何约束,导致集中采购和分散采购的定义越来越不确定。只要各单位、各部门有“特殊需求”的申请,监管部门就可以批准为部门集中采购,也就可以合法地规避法律的强制性规定。

政府依法设立集中采购机构就是要落实和推行集中采购制度,将原来分散在各采购人的采购权依法集中并赋予政府集中采购机构来统一行使和统一规范。然而,与立法初衷相违的是,采购制度实施后,招标代理公司如雨后春笋般地快速发展壮大,与各级政府集中采购机构并驾齐驱,形成了以营利为目的招标公司与非营利为目的各级集中采购机构共同代理政府采购业务的局面。前者虽然不属于我国政府采购模式之一,但法律没有禁止其代理政府采购业务。这样一来,我国政府采购的组织形式客观上也就包括了三类主体,即集中采购机构、各部门采购机构、以营利为目的招标公司。后一采购主体的业务量远远地超越了各级政府采购中心。这是非常不正常的现象。世界上一些政府采购制度比较成功的国家,很少有以营利为目的社会中介机构代理政府采购业务。由于中介机构依附于公共权力部门,行使着采购人的权力,客观上又躲避了法律的监督,从而演绎了一场场暗箱操作的黑幕,严重损害了政府采购在人们心目中的形象。为了规范政府采购的组织形式,我国的立法应禁止中介的招标公司代理政府采购业务。或者通过公开招标的政府采购方式选择几家社会中介机构代理政府采购业务。?(5)?


中共中央组织部、人事部关于在地方政府机构改革中做好人员定岗分流工作的通知

中共中央组织部 人事部


中共中央组织部、人事部关于在地方政府机构改革中做好人员定岗分流工作的通知
中共中央组织部 人事部



为贯彻中共中央、国务院《关于地方政府机构改革的意见》(中发〔1999〕2号)文件精神,保证地方政府机构改革健康顺利进行,逐步建立办事高效、运转协调、行为规范的地方行政管理体制,完善公务员制度,建设高素质的专业化公务员队伍,现就地方政府机构改革中做好人
员定岗分流和加强职位管理工作通知如下,请各地结合实际,认真贯彻执行。
一、积极运用竞争上岗方式做好人员定岗工作
在地方政府机构改革中,要坚持党管干部的原则,认真贯彻干部“四化”方针,按照“工作需要、群众参与、综合考评、组织决定”的原则,积极运用竞争上岗的方式,做好人员定岗工作。
(一)进一步加大竞争上岗工作力度。这次地方政府机构改革精简力度大、分流人员多,积极运用竞争上岗的方式做好人员定岗工作,不仅有利于机构改革的顺利进行,而且对于建立竞争激励机制,促进公务员能上能下、能进能出,提高公务员队伍整体素质,防止和克服用人上的不正
之风,具有重要意义。各地要以这次机构改革为契机,大力推行竞争上岗。各级地方政府工作部门内设机构的领导职位,原则上都应通过竞争上岗的方式确定人选。有条件的地方和部门,竞争上岗的范围可以扩大到科级以上非领导职位。一般职位也应引入竞争机制,采用竞争上岗与双向选
择相结合的办法确定人选。开展竞争上岗,一般在本部门现有同级职务人员中进行,根据实际情况,也可允许符合晋升条件的下一级职务人员参与竞争。
(二)严格按照程序实施竞争上岗。要按照中组部、人事部下发的《关于党政机关推行竞争上岗的意见》(组通字〔1998〕33号)规定的原则、范围、程序、方法组织实施竞争上岗。要联系本地区本部门实际,制定切实可行的具体实施方案。方案一经公布,必须严格执行,不得
在实施过程中随意更改。在实施竞争上岗过程中,要做到程序与办法、职位与任职条件、候选人、笔试面试(演讲答辩)成绩和竞争结果公开,增加工作的透明度,接受群众监督。上岗人选的确定,要扩大民主,把群众评价作为重要依据之一;要全面综合考虑笔试、面试(演讲答辩)成绩
、民主测评和组织考察结果;要按照干部管理权限,由党委(党组)集体讨论决定。
(三)结合竞争上岗积极实施轮岗和回避制度。在这次机构改革中,对政府工作部门内部在同一领导职位任职五年以上的,从事人、财、物管理的,负责证、照、牌核发以及项目、经费、配额审批的公务员,凡符合轮岗条件的,都要进行轮岗,轮岗数量一般要达到科级以上同级职位总
数的30%以上。要认真执行回避制度,对现有应回避的人员,必须实行回避,同时防止新的应回避现象的产生。
二、积极稳妥地做好人员分流工作
做好人员分流工作关系到大局的稳定,各级党委、政府必须高度重视。要按照“带职分流、定向培训、加强企业、优化结构”的原则,从本地区、本部门的实际出发,精心组织,积极稳妥地做好这项工作。
(一)积极开拓分流渠道,妥善安排分流人员。要按照中央确定的人员分流安排的基本原则,结合各地实际,制定切实可行的人员分流安排措施,广开分流渠道,多途径妥善安排分流人员。对希望离职参加学习培训的,应予支持。鼓励分流人员自谋职业或经办、创办企业和公益性事业
单位,充分发挥分流人员的专长和优势。
(二)严格执行国家的有关政策规定。政府机关分流人员,不得违反政策办理提前退休,不准搞停薪留职或留薪留职,严禁采取买断工龄的做法变相鼓励提前退休。自谋职业的,省级机关仅限科级及科级以下人员。市、县、乡级政府机关自谋职业人员的有关规定,由各省(区、市)结
合本地实际确定。对自谋职业人员,可一次性发给相当于本人三年基本工资的退职金。在涉及国家安全、机密等特殊职位上工作的人员,需在解密期满后,方可辞职。分流人员兴办经济实体,必须与原行政机关脱钩。
(三)要按照中央统一部署,抓紧做好分流人员安排工作。用三年左右时间完成分流任务,有条件的地区和部门要力争提前完成,贫困、边远及少数民族地区经批准可以适当延长。对暂时未安排出去的分流人员,要相对集中管理。
三、进一步加强公务员职位管理工作
职位设置是公务员管理的基础,人员定岗必须以职位设置为依据。各地要结合机构改革,进一步加强职位管理,使之制度化、规范化。
(一)要在机构改革“三定”方案规定的编制限额内,以工作性质、责任轻重、工作难易程度和所需资格条件为依据,调整和设置职位,并修订或编制相应的职位说明书,明确职位的任职资格条件,作为人员定岗工作的依据。要注意总结经验,从实际出发,使职位说明书科学合理、简
便易行。要严格按照“三定”方案设置各级领导职位,同时按照《国家公务员非领导职务设置办法》(国发〔1993〕78号附件二)的有关规定,重新核定非领导职务的职数,设置非领导职位。不得突破机构规格、职数限额或放宽任职条件设置、任命领导职务和非领导职务。
(二)对因机构调整等原因出现的领导职数和非领导职数超限额的问题,应制定措施,明确期限,尽快消化解决。凡超职数的单位,不得提拔任命新的领导职务和非领导职务。
(三)要结合机构改革,认真清理和纠正过去在职位管理方面存在的问题。地方政府机关的机构规格、名称和相应公务员的职级、职务名称等,必须符合国家的有关规定,不得自行提高规格、职级或改变名称、随意设置职位。在这次机构改革中,应按照国家的有关规定,对这方面存在
的问题,进行认真清理纠正。
四、加强对人员定岗分流和职位管理工作的组织领导
(一)各级党委和政府要从战略高度出发,充分认识做好人员定岗分流工作的重要意义,着眼于优化结构,改善素质,提高效率。各级党委和政府主要负责同志负总责,组织、人事、编制部门要密切配合,加强指导和协调工作。在这次机构改革中不再保留的部门,也要留一至二名领导
人员负责善后工作。
(二)要把人员定岗分流工作做深、做细、做实。要坚持党的原则,充分发扬民主,走群众路线,在广泛征求群众意见的基础上,制定切实可行的人员定岗分流实施方案,各级组织人事部门要对实施方案进行审核把关。要发挥党的政治优势,做好思想政治工作。针对分流人员的思想动
态和实际情况,广泛开展谈心活动,消除疑虑,化解矛盾,使他们自觉服从组织安排。对暂时未安排的分流人员,要从政治上、生活上多加关心,使他们感受到组织的关心和爱护。在机构改革中,各地各单位都要切实做到思想不散、秩序不乱、工作不断,保持正常的工作秩序。
(三)在机构改革和人员调整中,要严格组织人事纪律。各地要按照定岗分流有关规定,做到不徇私情,不封官许愿,不借机打击报复,不搞任人唯亲,不突击提拔干部和超职数配备干部。对违反干部人事工作纪律的,要严肃处理并追究责任。要严格执行国家财经纪律,坚决杜绝擅自
处理甚至转移、私分机关钱物现象的发生,严防国有资产流失。
地方其他机关进行机构改革时,人员定岗分流和职位管理工作可参照本《通知》执行。



1999年11月24日